StockData
Cue Biopharma, Inc. logo

Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/30
$16.12−1.38 (-7.89%)

Close on Nov 13, 2026Market cap $117.10MP/E –Yield –

Earnings

Cue Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 11, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$7.90M
+163.3% on a year earlier
EPS, Q2 FY2026
–
-$0.09 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Cue Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 11, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 14, 2026after the close$7.90M+163.3%–Release
Q4 FY2025ended Dec 31, 2025Mar 16, 2026after the close$21.90M+1268.8%$0.01Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close$2.10M-36.4%-$0.07Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close$3.00M–-$0.09Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close$400.00K-76.5%-$0.17Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025after the close$1.60M––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024after the close$3.30M––Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$1.70M–-$0.25Release
Q1 FY2020ended Mar 31, 2020May 19, 2020after the close–––Filing
Q4 FY2019ended Dec 31, 2019Mar 17, 2020after the close–––Filing
Q3 FY2019ended Sep 30, 2019Nov 12, 2019after the close–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Cue Biopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Cue Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Cue Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Cue Biopharma Announces Positive Topline Results from CUE-221
    Update
  2. 2026 ©© 20 20 26 26 C C ue ue B B ioip oh pa hr a ma rma ©2024 Cue Biopharma CONFIDENTIAL DO NOT DISTRIBUTE
    Update
  3. Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
    Results
  4. Cue Biopharma Announces $50.0 Million Private Placement
    News
  5. Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage
    News
  6. Cue Biopharma Announces $30 Million Private Placement
    News
  7. Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
    Results
  8. Cue Biopharma Announces Pricing of $10 Million Public Offering
    News
  9. 8-K exhibit EX-99.1
    Update
  10. Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
    Results
  11. Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop
    Update
  12. Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
    Results
  13. Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
    Results
  14. Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
    Results
  15. Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
    Results

See a number that looks wrong?